These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Drug Development. Are trade secrets delaying biosimilars? Price WN; Rai AK Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034 [No Abstract] [Full Text] [Related]
27. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings. Kelley T Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517 [TBL] [Abstract][Full Text] [Related]
28. How biosimilars will impact costs and care in oncology. Lyman GH Clin Adv Hematol Oncol; 2019 Oct; 17(10):544-547. PubMed ID: 31730579 [No Abstract] [Full Text] [Related]
29. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Grabowski HG; Guha R; Salgado M Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955 [TBL] [Abstract][Full Text] [Related]
30. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. Stergiopoulos S; Getz K Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298 [TBL] [Abstract][Full Text] [Related]
31. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet. Rychlick N Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768 [TBL] [Abstract][Full Text] [Related]
32. Biosimilars in the Caribbean--key considerations. Cox SD West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222 [No Abstract] [Full Text] [Related]
33. The economic implications of biosimilars. Singh SC; Bagnato KM Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809 [TBL] [Abstract][Full Text] [Related]
34. Bullying biosimilars: cheaper drugs stymied in USA. The Lancet Gastroenterology Hepatology Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669 [No Abstract] [Full Text] [Related]
35. Sequestration to slash research grants and delay biosimilars. Fox JL Nat Biotechnol; 2013 Apr; 31(4):271. PubMed ID: 23563405 [No Abstract] [Full Text] [Related]
36. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics. Wright EE; Blevins TC; Reed B; Pollom RD J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404 [TBL] [Abstract][Full Text] [Related]
37. The brave new world of biosimilars ('similar biologics') in India. Jois R Postgrad Med J; 2017 Oct; 93(1104):577-579. PubMed ID: 28546231 [No Abstract] [Full Text] [Related]
38. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. Hernandez I; Good CB; Shrank WH; Gellad WF JAMA; 2019 Apr; 321(16):1627-1629. PubMed ID: 30907933 [TBL] [Abstract][Full Text] [Related]
39. A long war begins: biosimilars versus patented biologics. Bocquet F; Paubel P J Med Econ; 2015; 18(12):1071-3. PubMed ID: 26212478 [No Abstract] [Full Text] [Related]
40. The comparability conundrum: biosimilars in the United States, Europe and Canada. Courage N; Parsons A Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]